TY - JOUR T1 - Rituximab-induced pneumonitis mimicking miliary tuberculosis JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 587 LP - 588 DO - 10.1183/09059180.00003813 VL - 22 IS - 130 AU - Chih-Wei Yao AU - Wei-Chih Liao AU - Chih-Yen Tu AU - Hung-Jen Chen AU - Guan-Chin Teseng AU - Su-Peng Yeh Y1 - 2013/12/01 UR - http://err.ersjournals.com/content/22/130/587.abstract N2 - To the Editor:Rituximab, a chimeric anti-CD20 monoclonal antibody, is commonly being used in combination with chemotherapy regimens in the standard treatment of B-cell non-Hodgkin lymphoma (NHL) [1]. Rituximab is considered to be a relatively safe drug but recently, severe and fatal interstitial lung disease (ILD) was noted with an occurrence rate of 0.01–0.03% [2]. Computed tomography (CT) patterns of rituximab-induced ILD include focal (54%) or diffused (9%) alveolar patterns and macronodules (3%), or ground-glass patterns (34%) [2]. In this regard, we report a patient with NHL in whom ILD developed after six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy with diffused micronodules mimicking miliary tuberculosis (TB). … ER -